WuXi XDC Cayman Inc (HKSE: 2268.HK) Stock Competitors & Peer Comparison

WuXi XDC Cayman Inc (HKSE: 2268.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2268.HK stands at 101.5B. In comparison, 2359.HK has a market cap of 591.4B. Regarding current trading prices, 2268.HK is priced at HK$80.15 on the HKSE, while 2359.HK trades at HK$204.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2268.HK currently has a P/E ratio of 62.96, whereas 2359.HK's P/E ratio is 23.53. In terms of profitability, 2268.HK's ROE is +0.14%, compared to 2359.HK's ROE of +0.27%. Regarding short-term risk, 2268.HK is more volatile compared to 2359.HK. This indicates higher risk in terms of short-term price fluctuations for 2268.HK.Check 2359.HK's competition here

WuXi XDC Cayman Inc (HKSE: 2268.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2268.HK stands at 101.5B. In comparison, 6127.HK has a market cap of 34.6B. Regarding current trading prices, 2268.HK is priced at HK$80.15 on the HKSE, while 6127.HK trades at HK$25.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2268.HK currently has a P/E ratio of 62.96, whereas 6127.HK's P/E ratio is 33.29. In terms of profitability, 2268.HK's ROE is +0.14%, compared to 6127.HK's ROE of +0.06%. Regarding short-term risk, 2268.HK is more volatile compared to 6127.HK. This indicates higher risk in terms of short-term price fluctuations for 2268.HK.Check 6127.HK's competition here

WuXi XDC Cayman Inc (HKSE: 2268.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2268.HK stands at 101.5B. In comparison, 9860.HK has a market cap of 2.7B. Regarding current trading prices, 2268.HK is priced at HK$80.15 on the HKSE, while 9860.HK trades at HK$3.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2268.HK currently has a P/E ratio of 62.96, whereas 9860.HK's P/E ratio is 84.42. In terms of profitability, 2268.HK's ROE is +0.14%, compared to 9860.HK's ROE of N/A. Regarding short-term risk, 2268.HK is more volatile compared to 9860.HK. This indicates higher risk in terms of short-term price fluctuations for 2268.HK.Check 9860.HK's competition here

WuXi XDC Cayman Inc (HKSE: 2268.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2268.HK stands at 101.5B. In comparison, 2251.HK has a market cap of 966.9M. Regarding current trading prices, 2268.HK is priced at HK$80.15 on the HKSE, while 2251.HK trades at HK$9.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2268.HK currently has a P/E ratio of 62.96, whereas 2251.HK's P/E ratio is -35.89. In terms of profitability, 2268.HK's ROE is +0.14%, compared to 2251.HK's ROE of -0.02%. Regarding short-term risk, 2268.HK is more volatile compared to 2251.HK. This indicates higher risk in terms of short-term price fluctuations for 2268.HK.Check 2251.HK's competition here

WuXi XDC Cayman Inc (HKSE: 2268.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2268.HK stands at 101.5B. In comparison, 9960.HK has a market cap of 955.8M. Regarding current trading prices, 2268.HK is priced at HK$80.15 on the HKSE, while 9960.HK trades at HK$0.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2268.HK currently has a P/E ratio of 62.96, whereas 9960.HK's P/E ratio is -14.05. In terms of profitability, 2268.HK's ROE is +0.14%, compared to 9960.HK's ROE of -0.02%. Regarding short-term risk, 2268.HK is more volatile compared to 9960.HK. This indicates higher risk in terms of short-term price fluctuations for 2268.HK.Check 9960.HK's competition here

WuXi XDC Cayman Inc (HKSE: 2268.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2268.HK stands at 101.5B. In comparison, 8037.HK has a market cap of 605M. Regarding current trading prices, 2268.HK is priced at HK$80.15 on the HKSE, while 8037.HK trades at HK$0.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2268.HK currently has a P/E ratio of 62.96, whereas 8037.HK's P/E ratio is -3.03. In terms of profitability, 2268.HK's ROE is +0.14%, compared to 8037.HK's ROE of -0.31%. Regarding short-term risk, 2268.HK is more volatile compared to 8037.HK. This indicates higher risk in terms of short-term price fluctuations for 2268.HK.Check 8037.HK's competition here

WuXi XDC Cayman Inc (HKSE: 2268.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2268.HK stands at 101.5B. In comparison, 2325.HK has a market cap of 348.3M. Regarding current trading prices, 2268.HK is priced at HK$80.15 on the HKSE, while 2325.HK trades at HK$0.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2268.HK currently has a P/E ratio of 62.96, whereas 2325.HK's P/E ratio is -1.29. In terms of profitability, 2268.HK's ROE is +0.14%, compared to 2325.HK's ROE of +0.00%. Regarding short-term risk, 2268.HK is more volatile compared to 2325.HK. This indicates higher risk in terms of short-term price fluctuations for 2268.HK.Check 2325.HK's competition here

WuXi XDC Cayman Inc (HKSE: 2268.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2268.HK stands at 101.5B. In comparison, 8247.HK has a market cap of 201.2M. Regarding current trading prices, 2268.HK is priced at HK$80.15 on the HKSE, while 8247.HK trades at HK$3.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2268.HK currently has a P/E ratio of 62.96, whereas 8247.HK's P/E ratio is -7.63. In terms of profitability, 2268.HK's ROE is +0.14%, compared to 8247.HK's ROE of N/A. Regarding short-term risk, 2268.HK is more volatile compared to 8247.HK. This indicates higher risk in terms of short-term price fluctuations for 2268.HK.Check 8247.HK's competition here

WuXi XDC Cayman Inc (HKSE: 2268.HK) plays a significant role within the Healthcare sector. Its performance on the HKSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, 2268.HK stands at 101.5B. In comparison, 0928.HK has a market cap of 190.6M. Regarding current trading prices, 2268.HK is priced at HK$80.15 on the HKSE, while 0928.HK trades at HK$0.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

2268.HK currently has a P/E ratio of 62.96, whereas 0928.HK's P/E ratio is 13.29. In terms of profitability, 2268.HK's ROE is +0.14%, compared to 0928.HK's ROE of +0.01%. Regarding short-term risk, 2268.HK is more volatile compared to 0928.HK. This indicates higher risk in terms of short-term price fluctuations for 2268.HK.Check 0928.HK's competition here